

EVOTEC EXPANDS iPSC PLATFORM WITH LICENCE FROM ID PHARMA

- ▶ *EVOTEC RECEIVES NON-EXCLUSIVE LICENCE TO DERIVE AND UTILISE CELLS FROM IPSCS CREATED WITH ID PHARMA'S VIRUS VECTOR TECHNOLOGY*
- ▶ *THE LICENCE ENHANCES EVOTEC'S PATIENT-DERIVED iPSC CAPABILITIES FOR TREATMENTS OF NERVOUS SYSTEM DISEASES AND DIABETES*

Hamburg, Germany, 23 May 2018:

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has expanded its iPSC platform through a licence agreement with ID Pharma. The non-exclusive licence enables Evotec to both work with and differentiate induced pluripotent stem cells (“iPSC”) produced with ID Pharma’s Sendai virus (“SeV”) vector technology.

The new licence is an important addition to Evotec’s iPSC platform, one of the most comprehensive in the industry. It further enhances Evotec’s broad iPSC capabilities in early drug discovery for treatments of a variety of conditions including nervous system diseases and diabetes.

About Evotec’s iPSC platform

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec has developed this platform, which is part of Evotec’s EVT Innovate business segment, to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards. This effort was initially enabled by a research collaboration and licence agreement with Harvard University involving world-leading scientists at the Harvard Stem Cell Institute. Since then, Evotec’s efforts have grown, and due to its expertise, Evotec has established collaborations with Celgene, Sanofi, DFG Research Centre for Regenerative Therapies Dresden, Censo Biotechnologies and Fraunhofer IME-SP to advance its broad iPSC platform. In addition, Evotec is working closely with academic institutions to further broaden and strengthen Evotec’s efforts and investment in iPSC applications.

ABOUT ID PHARMA

ID Pharma is a Japanese bio-venture company, which handles the advanced medical treatment business of the From Group (Tokyo Stock Exchange: 2372). ID Pharma possesses world-class technologies for developing and producing vectors and is highly regarded by the biotechnology sector. In particular, the Sendai virus (“SeV”) vector, an original fundamental technology of ID Pharma, has an excellent safety profile and gene transfer efficiency and is expected to become a leading vector. The company also operates a cGMP facility and cell processing centre (CPC) in Ibaraki, Japan, and offers contract manufacturing services utilising SeV for clinical use. In addition, ID Pharma is exploiting its gene transfer capabilities through enhancement of its vector platform and by promoting the development of medical technologies e.g. gene therapy for critical limb ischemia.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, infectious diseases, diabetes and complications of diabetes, pain, inflammation, and oncology and. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi and UCB and development partnerships with e.g. Sanofi in the field of diabetes, Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information, please go to www.evotec.com and follow us on Twitter [@EvotecAG](https://twitter.com/EvotecAG).

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.